|
1
|
Smyth EC, Lagergren J, Fitzgerald RC,
Lordick F, Shah MA, Lagergren P and Cunningham D: Oesophageal
cancer. Nat Rev Dis Primers. 3:170482017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zeng H, Zheng R, Zhang S, Zuo T, Xia C,
Zou X and Chen W: Esophageal cancer statistics in China, 2011:
Estimates based on 177 cancer registries. Thorac Cancer. 7:232–237.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Office for National Statistics, . Cancer
survival in England: Patients diagnosed 2006–2010 and followed up
to 2011. Newport: Office for National Statistics; 2012
|
|
4
|
Hanawa M, Suzuki S, Dobashi Y, Yamane T,
Kono K, Enomoto N and Ooi A: EGFR protein overexpression and gene
amplification in squamous cell carcinomas of the esophagus. Int J
Cancer. 118:1173–1180. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mendelsohn J and Baselga J: Status of
epidermal growth factor receptor antagonists in the biology and
treatment of cancer. J Clin Oncol. 21:2787–2799. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Teraishi F, Kagawa S, Watanabe T, Tango Y,
Kawashima T, Umeoka T, Nisizaki M, Tanaka N and Fujiwara T: ZD1839
(Gefitinib, ‘Iressa’), an epidermal growth factor receptor-tyrosine
kinase inhibitor, enhances the anti-cancer effects of TRAIL in
human esophageal squamous cell carcinoma. FEBS Lett. 579:4069–4075.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hara F, Aoe M, Doihara H, Taira N, Shien
T, Takahashi H, Yoshitomi S, Tsukuda K, Toyooka S, Ohta T and
Shimizu N: Antitumor effect of gefitinib (‘Iressa’) on esophageal
squamous cell carcinoma cell lines in vitro and in vivo. Cancer
Lett. 226:37–47. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wei Z, Ma W, Qi X, Zhu X, Wang Y, Xu Z,
Luo J, Wang D, Guo W, Li X, et al: Pinin facilitated proliferation
and metastasis of colorectal cancer through activating EGFR/ERK
signaling pathway. Oncotarget. 7:29429–29439. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Baselga J and Arteaga CL: Critical update
and emerging trends in epidermal growth factor receptor targeting
in cancer. J Clin Oncol. 23:2445–2459. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sutter AP, Höpfner M, Huether A, Maaser K
and Scherübl H: Targeting the epidermal growth factor receptor by
erlotinib (Tarceva) for the treatment of esophageal cancer. Int J
Cancer. 118:1814–1822. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carey KD, Garton AJ, Romero MS, Kahler J,
Thomson S, Ross S, Park F, Haley JD, Gibson N and Sliwkowski MX:
Kinetic analysis of epidermal growth factor receptor somatic mutant
proteins shows increased sensitivity to the epidermal growth factor
receptor tyrosine kinase inhibitor, erlotinib. Cancer Res.
66:8163–8171. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Saxena S, Jonsson ZO and Dutta A: Small
RNAs with imperfect match to endogenous mRNA repress translation.
Implications for off-target activity of small inhibitory RNA in
mammalian cells. J Biol Chem. 278:44312–44319. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yanaihara N, Caplen N, Bowman E, Seike M,
Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et
al: Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Voorhoeve PM, le Sage C, Schrier M, Gillis
AJ, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A,
et al: A genetic screen implicates miRNA-372 and miRNA-373 as
oncogenes in testicular germ cell tumors. Cell. 124:1169–1181.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kent OA and Mendell JT: A small piece in
the cancer puzzle: microRNAs as tumor suppressors and oncogenes.
Oncogene. 25:6188–6196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ma W, Yu J, Qi X, Liang L, Zhang Y and
Ding Y, Lin X, Li G and Ding Y: Radiation-induced MicroRNA-622
inhibits radiosensitivity in colorectal cancer cells by targeting
Rb. Oncotarget. 6:15984–15994. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Meng F, Henson R, Wehbe-Janek H, Ghoshal
K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the
PTEN tumor suppressor gene in human hepatocellular cancer.
Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lu XJ, Qi X, Zheng DH and Ji LJ: Modelling
cancer processes with CRISPR-Cas9. Trends Biotechnol. 33:317–319.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yan D, Dong Xda E, Chen X, Wang L, Lu C,
Wang J, Qu J and Tu L: MicroRNA-1/206 targets c-Met and inhibits
rhabdomyosarcoma development. J Biol Chem. 284:29596–29604. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nasser MW, Datta J, Nuovo G, Kutay H,
Motiwala T, Majumder S, Wang B, Suster S, Jacob ST and Ghoshal K:
Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression
of tumorigenic property of lung cancer cells and their
sensitization to doxorubicin-induced apoptosis by miR-1. J Biol
Chem. 283:33394–33405. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Leone V, D'Angelo D, Rubio I, de Freitas
PM, Federico A, Colamaio M, Pallante P, Medeiros-Neto G and Fusco
A: MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting
CCND2, CXCR4, and SDF-1alpha. J Clin Endocrinol Metab.
96:E1388–E1398. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kojima S, Chiyomaru T, Kawakami K, Yoshino
H, Enokida H, Nohata N, Fuse M, Ichikawa T, Naya Y, Nakagawa M and
Seki N: Tumour suppressors miR-1 and miR-133a target the oncogenic
function of purine nucleoside phosphorylase (PNP) in prostate
cancer. Br J Cancer. 106:405–413. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hudson RS, Yi M, Esposito D, Watkins SK,
Hurwitz AA, Yfantis HG, Lee DH, Borin JF, Naslund MJ, Alexander RB,
et al: MicroRNA-1 is a candidate tumor suppressor and prognostic
marker in human prostate cancer. Nucleic Acids Res. 40:3689–3703.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoshino H, Enokida H, Chiyomaru T,
Tatarano S, Hidaka H, Yamasaki T, Gotannda T, Tachiwada T, Nohata
N, Yamane T, et al: Tumor suppressive microRNA-1 mediated novel
apoptosis pathways through direct inhibition of splicing factor
serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer. Biochem
Biophys Res Commun. 417:588–593. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Migliore C, Martin V, Leoni VP, Restivo A,
Atzori L, Petrelli A, Isella C, Zorcolo L, Sarotto I, Casula G, et
al: MiR-1 downregulation cooperates with MACC1 in promoting MET
overexpression in human colon cancer. Clin Cancer Res. 18:737–747.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Datta J, Kutay H, Nasser MW, Nuovo GJ,
Wang B, Majumder S, Liu CG, Volinia S, Croce CM, Schmittgen TD, et
al: Methylation mediated silencing of MicroRNA-1 gene and its role
in hepatocellular carcinogenesis. Cancer Res. 68:5049–5058. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao Q, Zhang B, Shao Y, Chen L, Wang X,
Zhang Z, Shu Y and Guo R: Correlation between the expression levels
of microRNA-1 and PIK3CA in non-small-cell lung cancer and their
relationship with clinical characteristics and prognosis. Future
Oncol. 10:49–57. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nohata N, Sone Y, Hanazawa T, Fuse M,
Kikkawa N, Yoshino H, Chiyomaru T, Kawakami K, Enokida H, Nakagawa
M, et al: miR-1 as a tumor suppressive microRNA targeting TAGLN2 in
head and neck squamous cell carcinoma. Oncotarget. 2:29–42. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo Y, Chen Z, Zhang L, Zhou F, Shi S,
Feng X, Li B, Meng X, Ma X, Luo M, et al: Distinctive microRNA
profiles relating to patient survival in esophageal squamous cell
carcinoma. Cancer Res. 68:26–33. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen H, Guan R, Lei Y, Chen J, Ge Q, Zhang
X, Dou R, Chen H, Liu H, Qi X, et al: Lymphangiogenesis in gastric
cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis. BMC Cancer.
15:1032015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Akagi I, Miyashita M, Makino H, Nomura T,
Hagiwara N, Takahashi K, Cho K, Mishima T, Ishibashi O, Ushijima T,
et al: Overexpression of PIK3CA is associated with lymph node
metastasis in esophageal squamous cell carcinoma. Int J Oncol.
34:767–775. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang YL, Chu JY, Luo ML, Wu YP, Zhang Y,
Feng YB, Shi ZZ, Xu X, Han YL, Cai Y, et al: Amplification of
PRKCI, located in 3q26, is associated with lymph node metastasis in
esophageal squamous cell carcinoma. Genes Chromosomes Cancer.
47:127–136. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wada S, Noguchi T, Takeno S and Kawahara
K: PIK3CA and TFRC located in 3q are new prognostic factors in
esophageal squamous cell carcinoma. Ann Surg Oncol. 13:961–966.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu QQ, Wu H, Huang X, Shen H, Shu YQ,
Zhang B, Xiang CC, Yu SM, Guo RH and Chen L: miR-1 targets PIK3CA
and inhibits tumorigenic properties of A549 cells. Biomed
Pharmacother. 68:155–161. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mönig SP and Hölscher AH: Clinical
classification systems of adenocarcinoma of the esophagogastric
junction. Recent Results Cancer Res. 182:19–28. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vanhaesebroeck B, Stein RC and Waterfield
MD: The study of phosphoinositide 3-kinase function. Cancer Surv.
27:249–270. 1996.PubMed/NCBI
|
|
39
|
Andjelković M, Alessi DR, Meier R,
Fernandez A, Lamb NJ, Frech M, Cron P, Cohen P, Lucocq JM and
Hemmings BA: Role of translocation in the activation and function
of protein kinase B. J Biol Chem. 272:31515–31524. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bianco C, Tortora G, Bianco R, Caputo R,
Veneziani BM, Caputo R, Damiano V, Troiani T, Fontanini G, Raben D,
et al: Enhancement of antitumor activity of ionizing radiation by
combined treatment with the selective epidermal growth factor
receptor tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer
Res. 8:3250–3258. 2002.PubMed/NCBI
|
|
42
|
Qi X, Zhang L and Lu X: New insights into
epithelial-to-mesenchymal transition in cancer. Trends Pharmacol
Sci. 37:246–248. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sirotnak FM, Zakowski MF, Miller VA, Scher
HI and Kris MG: Efficacy of cytotoxic agents against human tumor
xenografts is markedly enhanced by coadministration of ZD1839
(Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res.
6:4885–4892. 2000.PubMed/NCBI
|
|
44
|
Baselga J, Rischin D, Ranson M, Calvert H,
Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, et al:
Phase I safety, pharmacokinetic, and pharmacodynamic trial of
ZD1839, a selective oral epidermal growth factor receptor tyrosine
kinase inhibitor, in patients with five selected solid tumor types.
J Clin Oncol. 20:4292–4302. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Iihara K, Shiozaki H, Tahara H, Kobayashi
K, Inoue M, Tamura S, Miyata M, Oka H, Doki Y and Mori T:
Prognostic significance of transforming growth factor-alpha in
human esophageal carcinoma. Implication for the autocrine
proliferation. Cancer. 71:2902–2909. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ozawa S, Ueda M, Ando N, Abe O and Shimizu
N: High incidence of EGF receptor hyperproduction in esophageal
squamous-cell carcinomas. Int J Cancer. 39:333–337. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dutton SJ, Ferry DR, Blazeby JM, Abbas H,
Dahle-Smith A, Mansoor W, Thompson J, Harrison M, Chatterjee A,
Falk S, et al: Gefitinib for oesophageal cancer progressing after
chemotherapy (COG): A phase 3, multicentre, double-blind,
placebo-controlled randomised trial. Lancet Oncol. 15:894–904.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Adelstein DJ, Rodriguez CP, Rybicki LA,
Ives DI and Rice TW: A phase II trial of gefitinib for recurrent or
metastatic cancer of the esophagus or gastroesophageal junction.
Invest New Drugs. 30:1684–1689. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Janmaat ML, Kruyt FA, Rodriguez JA and
Giaccone G: Response to epidermal growth factor receptor inhibitors
in non-small cell lung cancer cells: Limited antiproliferative
effects and absence of apoptosis associated with persistent
activity of extracellular signal-regulated kinase or Akt kinase
pathways. Clin Cancer Res. 9:2316–2326. 2003.PubMed/NCBI
|
|
50
|
Meng F, Henson R, Lang M, Wehbe H,
Maheshwari S, Mendell JT, Jiang J, Schmittgen TD and Patel T:
Involvement of human micro-RNA in growth and response to
chemotherapy in human cholangiocarcinoma cell lines.
Gastroenterology. 130:2113–2129. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Weidhaas JB, Babar I, Nallur SM, Trang P,
Roush S, Boehm M, Gillespie E and Slack FJ: MicroRNAs as potential
agents to alter resistance to cytotoxic anticancer therapy. Cancer
Res. 67:11111–11116. 2007. View Article : Google Scholar : PubMed/NCBI
|
